Evidence map›Paper›PMID 36980916›Full record

ArticleGenes2023

Role of Genetic Thrombophilia Markers in Thrombosis Events in Elderly Patients with COVID-19.

Irina Fevraleva, Daria Mamchich, Dmitriy Vinogradov, Yulia Chabaeva, Sergey Kulikov, Tatiana Makarik, Vahe Margaryan, Georgiy Manasyan, Veronika Novikova, Svetlana Rachina and 2 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Frequency of Non-Type I/IIDiseases (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Irina FevralevaNational Medical Research Center for Hematology, Novy Zykovski Lane 4a, 125167 Moscow, Russia.
Daria MamchichHospital Therapy Department No. 2, I.M. Sechenov First Moscow State Medical University, RF Health Ministry, Bolshaya Pirogovskaya St. 2, Bld. 4, 119435 Moscow, Russia.ORCID 0000-0003-3331-4033
Dmitriy VinogradovHospital Therapy Department No. 2, I.M. Sechenov First Moscow State Medical University, RF Health Ministry, Bolshaya Pirogovskaya St. 2, Bld. 4, 119435 Moscow, Russia.
Yulia ChabaevaNational Medical Research Center for Hematology, Novy Zykovski Lane 4a, 125167 Moscow, Russia.
Sergey KulikovNational Medical Research Center for Hematology, Novy Zykovski Lane 4a, 125167 Moscow, Russia.
Tatiana MakarikNational Medical Research Center for Hematology, Novy Zykovski Lane 4a, 125167 Moscow, Russia.
Vahe MargaryanHospital Therapy Department No. 2, I.M. Sechenov First Moscow State Medical University, RF Health Ministry, Bolshaya Pirogovskaya St. 2, Bld. 4, 119435 Moscow, Russia.
Georgiy ManasyanHospital Therapy Department No. 2, I.M. Sechenov First Moscow State Medical University, RF Health Ministry, Bolshaya Pirogovskaya St. 2, Bld. 4, 119435 Moscow, Russia.
Veronika NovikovaHospital Therapy Department No. 2, I.M. Sechenov First Moscow State Medical University, RF Health Ministry, Bolshaya Pirogovskaya St. 2, Bld. 4, 119435 Moscow, Russia.
Svetlana RachinaHospital Therapy Department No. 2, I.M. Sechenov First Moscow State Medical University, RF Health Ministry, Bolshaya Pirogovskaya St. 2, Bld. 4, 119435 Moscow, Russia.ORCID 0000-0002-3329-7846
Georgiy MelkonyanWar Veterans Hospital N3, Startovaya St. 4, 129336 Moscow, Russia.
Karine LytkinaWar Veterans Hospital N3, Startovaya St. 4, 129336 Moscow, Russia.
Sechenov University · RUNational Medical Research Center for Hematology · RUMoscow Regional Psychiatry Hospital No.5 · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombosis is an extremely dangerous complication in elderly patients with COVID-19. Since the first months of the pandemic, anticoagulants have been mandatory in treatment protocols for patients with COVID-19, unless there are serious contraindications. We set out to discover if genetic thrombophilia factors continue to play a triggering role in the occurrence of thrombosis in patients with COVID-19 with prophylactic or therapeutic anticoagulants. We considered the following genetic markers as risk factors for thrombophilia: G1691A in the

Indexed as

COVID-19ThrombophiliaThrombosisAgedFactor VGenetic MarkersHumansProthrombinFactor VGenetic MarkersProthrombinhereditary mutationinherited thrombophiliareal-time AS-PCRthrombosis

Identifiers

PMID36980916
PMCPMC10048352
OpenAlexW4323313778

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read51
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.